Nektar Therapeutics (NKTR)

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.


455 Mission Bay Boulevard South
San Francisco, California 94158
United States



Get BioInvest's perspective on Nektar Therapeutic's CEO

Latest Company News

What Analysts are Predicting For CDK Global, Inc. (CDK), Nektar Therapeutics ... The USA Commerce - Feb 21, 2017 Shares of CDK Global, Inc. (NASDAQ:CDK) surged 0.71% to $65.47. During the trading on 02/17/2017, Company's stock ranged from $64.27 to $65.52. Stock Price of Nektar Therapeutics (NKTR) Decreases -1.43% - Highland Mirror Ivan P. Gergel Sells 1457 Shares of Nektar Therapeutics (NKTR) Stock - The Cerbat Gem [...]
Tue, Feb 21, 2017 12:11:00 PM, Continue reading at the source
Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and ... Yahoo Finance - Jan 25, 2017 Nektar Therapeutics' shares gained 1.00 percent to close at $12.14 a share Monday. The stock traded between $11.75 and $12.18 on volume of 967,112 shares traded. [...]
Wed, Jan 25, 2017 1:41:00 PM, Continue reading at the source
Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In ... Seeking Alpha - Jan 20, 2017 Topline data for three candidate drugs currently in Phase III trials (NKTR-181, Amikacin Inhale, and Ciprofloxacin DPI) expected in 1H 2017. News review of 2 biotech stocks: Nektar Therapeutics (NASDAQ:NKTR), Ophthotech ... - The Voice Registrar [...]
Fri, Jan 20, 2017 3:10:00 PM, Continue reading at the source
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the ... PR Newswire (press release) - Jan 5, 2017 SAN FRANCISCO, Jan. 5, 2017 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual J.P. [...]
Thu, Jan 05, 2017 2:03:00 PM, Continue reading at the source
Nektar Therapeutics Is Attractive Ahead Of Multiple Catalysts Seeking Alpha - Dec 6, 2016 Nektar Therapeutics (NASDAQ:NKTR) has two commercial products, movantik and adynovate, partnered with AstraZeneca (NYSE:AZN) and Baxter (NYSE:BAX) respectively, 5 partnered drug candidates in advanced stages of clinical trial, and these two ... [...]
Tue, Dec 06, 2016 7:52:00 PM, Continue reading at the source
Nektar Therapeutics' (NKTR) CEO Howard Robin on Q3 2016 Results - Earnings ... Seeking Alpha - Nov 4, 2016 Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Third Quarter 2016 Financial Results Conference Call. [...]
Fri, Nov 04, 2016 2:15:00 AM, Continue reading at the source
Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for ... PR Newswire (press release) - Oct 28, 2016 SAN FRANCISCO, Oct. 28, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which will be held November ... [...]
Fri, Oct 28, 2016 12:00:00 PM, Continue reading at the source
Nektar Therapeutics shares fall on secondary stock offering CNBC - Oct 19, 2016 Shares of Nektar Therapeutics shed about 5 percent Wednesday after the biotech company announced a secondary offering of common stock worth more than $175 million. Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing - [...]
Wed, Oct 19, 2016 3:31:00 PM, Continue reading at the source
Nektar Therapeutics' Sweet Pipeline Barron's - Aug 5, 2016 Nektar Therapeutics is on track to report top-line data from the dose-escalation stage of the Phase 1/2 NKTR-214 trial by year-end 2016, and the drug could be an ideal combination drug in the growing immunotherapy space. [...]
Fri, Aug 05, 2016 5:00:00 PM, Continue reading at the source
The Probable Reason Behind Nektar Therapeutics Inc.'s 15.5% Year-to-Date Drop Motley Fool - Jul 6, 2016 Nektar signed a European licensing agreement with Daiichi Sankyo Europe for Onzeald, its experimental drug candidate for breast and brain cancer. [...]
Wed, Jul 06, 2016 7:07:00 PM, Continue reading at the source